Posted in | News | Bionanotechnology

Gold Nanoparticles Deliver Anti Cancer Drugs with DNA

Scientists of the Chemistry Department at Syracuse University have developed a system to deliver drugs to treat cancer tumors using gold nanoparticles.

The attached DNA connects to an anti-cancer drug, Doxorubicin or DOX. Initial experiments show this could enhance chemotherapy results. DOX is at present used to treat cancers of the breast, bone marrow, thyroid, bladder, ovary and small cell lung. Professor James C. Dabrowiak says this could enhance the device molecules targeting cancer cells.

The DNA on the gold particles is designed to bind to the DOX anti-tumor drug. Studies show that the DOX can be diffused to be moved to a receptor DNA molecule. The gold nanoparticles measure about 15.5 nanometers in diameter. An individual nanoparticle delivers more than 100 DOX spots and could attack the tumor on a massive scale when multiplied. The anti-tumor drug DOX has been approved by FDA. The DNA could be designed to bind to other drug molecules to treat other diseases.

The work of the Syracuse University team was published in the February 2011 issue of ChemComm, a publication of the Royal Society of Chemistry.

Source: http://www.syr.edu/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Chai, Cameron. (2019, February 12). Gold Nanoparticles Deliver Anti Cancer Drugs with DNA. AZoNano. Retrieved on September 21, 2021 from https://www.azonano.com/news.aspx?newsID=21946.

  • MLA

    Chai, Cameron. "Gold Nanoparticles Deliver Anti Cancer Drugs with DNA". AZoNano. 21 September 2021. <https://www.azonano.com/news.aspx?newsID=21946>.

  • Chicago

    Chai, Cameron. "Gold Nanoparticles Deliver Anti Cancer Drugs with DNA". AZoNano. https://www.azonano.com/news.aspx?newsID=21946. (accessed September 21, 2021).

  • Harvard

    Chai, Cameron. 2019. Gold Nanoparticles Deliver Anti Cancer Drugs with DNA. AZoNano, viewed 21 September 2021, https://www.azonano.com/news.aspx?newsID=21946.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit